Abiraterone CAS No. 154229-19-3 (DMF) Anti-cancer drugs
02
introduce
Abiraterone is a potent selective CYP17A1 inhibitor API that blocks systemic androgen biosynthesis. It is the core raw material for first-line treatment of metastatic castration-resistant prostate cancer, significantly prolonging patient survival.
Our strict quality control ensures consistent batch performance for pharmaceutical production needs.
Our strict quality control ensures consistent batch performance for pharmaceutical production needs.
02
Physical and chemical properties
Abiraterone possesses key physical and chemical characteristics as follows:
- Melting Point: 227-228 °C
- Boiling Point: 500.2±50.0 °C
- Density: 1.14±0.1 g/cm³
- Storage Conditions: Sealed in dry, 2-8 °C
- Solubility: Slightly soluble in chloroform and methanol
- Melting Point: 227-228 °C
- Boiling Point: 500.2±50.0 °C
- Density: 1.14±0.1 g/cm³
- Storage Conditions: Sealed in dry, 2-8 °C
- Solubility: Slightly soluble in chloroform and methanol
Ultra-potent Target Inhibition
IC₅₀ of 2 nm against CYP17A1, irreversibly suppressing androgen synthesis from testes, adrenals and tumor tissue.
IC₅₀ of 2 nm against CYP17A1, irreversibly suppressing androgen synthesis from testes, adrenals and tumor tissue.
Broad Androgen Blockade
Reduces systemic testosterone levels to castrate range (<20 ng/dL), superior to conventional androgen deprivation therapy.
Reduces systemic testosterone levels to castrate range (<20 ng/dL), superior to conventional androgen deprivation therapy.
Proven Clinical Efficacy
Significantly extends overall survival and progression-free survival in both pre- and post-chemotherapy metastatic prostate cancer patients.
Significantly extends overall survival and progression-free survival in both pre- and post-chemotherapy metastatic prostate cancer patients.
Oral Bioavailability
Well-absorbed orally, convenient for outpatient treatment with good patient compliance.
Well-absorbed orally, convenient for outpatient treatment with good patient compliance.
Favorable Safety Profile
Manageable adverse reactions when combined with prednisone, suitable for long-term administration.
Manageable adverse reactions when combined with prednisone, suitable for long-term administration.
Prostate Cancer Therapeutics
Core raw material for medications treating metastatic castration-resistant prostate cancer (mCRPC), both first-line and post-docetaxel settings.
Used in formulations for metastatic high-risk castration-sensitive prostate cancer (mCSPC) in combination with androgen deprivation therapy.
Core raw material for medications treating metastatic castration-resistant prostate cancer (mCRPC), both first-line and post-docetaxel settings.
Used in formulations for metastatic high-risk castration-sensitive prostate cancer (mCSPC) in combination with androgen deprivation therapy.
Clinical Research Applications
Investigational API for early-stage prostate cancer treatment and advanced breast cancer therapy development.
As the cornerstone of advanced prostate cancer treatment, Abiraterone has become an essential raw material for global pharmaceutical manufacturers, with expanding research potential in other oncology indications.
Contact our team today for sample requests, technical specifications and bulk order inquiries—we’re committed to providing efficient and customized pharmaceutical material solutions for you.
Contact our team today for sample requests, technical specifications and bulk order inquiries—we’re committed to providing efficient and customized pharmaceutical material solutions for you.